Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Nov 12, 2015 11:55pm
321 Views
Post# 24287755

RE:Most obvious undervaluation parameter...

RE:Most obvious undervaluation parameter...I cant take issue with anything you say plilong,  in fact i agree with almost everything u say.  Where we differ perhaps is the fact that i am IN this in a big way because of that value  disconnect because i believe that the value will be unlocked given the current path.

I am gonna go out on a limb and predict this stock closes up meaningfully tommorrow,  perhaps even testing previous all time highs.  I think u will get very positive morning updates from the major analysts outlining recent process and this latest deal.  I just cant imagine how PL could  have done this Omnio deal if the efficacy data wasnt compelling.   And if it truly is,  then we are going to see meaningful target revisions upward similar to cannacords.  Its exactly these kinds of real and tangible steps forward with compelling evidence,  that is going to bring both industry and institutions IN..... which will eventually close the valuation gap you so eloquently described

i would add,  despite the well documented over optimism Pierre has exhibited,  we wouldnt even be having this discussion if he werent such a visionary to bring this all to fruition
Bullboard Posts